Evidence map›Paper›PMID 28566424›Full record

ArticleScience translational medicine2017

Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief.

Dane D Jensen, TinaMarie Lieu, Michelle L Halls, Nicholas A Veldhuis, Wendy L Imlach, Quynh N Mai, Daniel P Poole, Tim Quach, Luigi Aurelio, Joshua Conner and 16 more

Open access · greenAbstract read
In one paragraph

Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 238 citations in OpenAlex.

  1. Dual-Targeted Inhibition of PARNanomaterials (Basel, Switzerland) · 2026
    Article
  2. Development of pH-Sensitive β‑Adrenergic Receptor Antagonists.ACS pharmacology & translational science · 2026
    Article
  3. Oncogenic Gα signaling requires AP-3-dependent recruitment to the endolysosomal compartment.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. The working lives of neuronal 5-HTRSC chemical biology · 2026
    Review
  5. Review
  6. Article
  7. MMP1 and PRSS23 induce PARCommunications biology · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. The contribution of endocytic mediators to itch transmission.bioRxiv : the preprint server for biology · 2026
    Article
  12. Endosomal MrGPRX1 signaling sensitizes TRPV1 to enhance itch.Frontiers in molecular neuroscience · 2026
    Article
  13. Article
  14. The contribution of endocytic mediators to itch transmission.Frontiers in molecular neuroscience · 2026
    Article
  15. Class A and B GPCRs trigger rapid GαCommunications biology · 2025
    Article
  16. Endosomal MrGPRX1 signaling sensitizes TRPV1 to enhance itch.bioRxiv : the preprint server for biology · 2025
    Article
  17. Nanomedicines targeting protease-activated receptor 2 in endosomes provide sustained analgesia.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  18. Emerging therapeutic approaches for treating abdominal pain.Journal of the Canadian Association of Gastroenterology · 2025
    Review
  19. Article
  20. Review

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 8 institutions in 5 countries.

Dane D JensenMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.ORCID 0000-0001-6540-2375
TinaMarie LieuMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.ORCID 0000-0003-4337-8970
Michelle L HallsMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.ORCID 0000-0001-8555-8959
Nicholas A VeldhuisMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Wendy L ImlachDiscipline of Pharmacology, University of Sydney, New South Wales 2006, Australia.ORCID 0000-0002-7521-9969
Quynh N MaiMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.ORCID 0000-0002-1860-844X
Daniel P PooleMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.ORCID 0000-0002-6168-8422
Tim QuachMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.ORCID 0000-0001-8611-2430
Luigi AurelioMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Joshua ConnerMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.ORCID 0000-0002-3650-0993
Carmen Klein HerenbrinkMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Nicholas BarlowMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Jamie S SimpsonMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.ORCID 0000-0002-8894-422X
Martin J ScanlonMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.ORCID 0000-0002-9230-7506
Bimbil GrahamMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Adam McCluskeySchool of Environmental and Life Sciences, University of Newcastle, New South Wales 2308, Australia.ORCID 0000-0001-7125-863X
Phillip J RobinsonChildren's Medical Research Institute, University of Sydney, New South Wales 2145, Australia.ORCID 0000-0002-7878-0313
Virginie EscriouUnité de Technologies Chimiques et Biologiques pour la Sante, CNRS UMR8258, INSERM U1022, Université Paris Descartes, Chimie ParisTech, 75006 Paris, France.
Romina NassiniDepartment of Health Sciences, Clinical Pharmacology Unit, University of Florence, 6-50139 Florence, Italy.ORCID 0000-0002-9223-8395
Serena MaterazziDepartment of Health Sciences, Clinical Pharmacology Unit, University of Florence, 6-50139 Florence, Italy.
Pierangelo GeppettiDepartment of Health Sciences, Clinical Pharmacology Unit, University of Florence, 6-50139 Florence, Italy.
Gareth A HicksTakeda Pharmaceuticals, Boston, MA 02139, USA.
Macdonald J ChristieDiscipline of Pharmacology, University of Sydney, New South Wales 2006, Australia.ORCID 0000-0002-0622-609X
Christopher J H PorterMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia. nb2733@cumc.columbia.edu chris.porter@monash.edu meri.canals@monash.edu.ORCID 0000-0003-3474-7551
Meritxell CanalsMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia. nb2733@cumc.columbia.edu chris.porter@monash.edu meri.canals@monash.edu.ORCID 0000-0002-7942-5006
Nigel W BunnettMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia. nb2733@cumc.columbia.edu chris.porter@monash.edu meri.canals@monash.edu.ORCID 0000-0003-3367-0644
Australian Research Council · AUMonash University · AUUniversity of Florence · ITThe University of Sydney · AUCentre National de la Recherche Scientifique · FRChildren's Medical Research Institute · AUTakeda (Japan) · JPUniversity of Newcastle Australia · AU

Funding

Endosomal Platforms for Signaling PainR01NS102722 · NINDS · NEW YORK UNIVERSITY · PI NIGEL W BUNNETT, Brian L Schmidt · 2017 to 2026
$3.4M
NINDS NIH HHS R01 NS102722
6 · The paper itself

Abstract

Typically considered to be cell surface sensors of extracellular signals, heterotrimeric GTP-binding protein (G protein)-coupled receptors (GPCRs) control many pathophysiological processes and are the target of 30% of therapeutic drugs. Activated receptors redistribute to endosomes, but researchers have yet to explore whether endosomal receptors generate signals that control complex processes in vivo and are viable therapeutic targets. We report that the substance P (SP) neurokinin 1 receptor (NK

Indexed as

Molecular Targeted TherapyNociceptionSignal TransductionAnimalsbeta-ArrestinsCell CompartmentationClathrinDynaminsEndocytosisEndosomesGTP-Binding ProteinsHEK293 CellsHumansLipidsModels, BiologicalNeurokinin-1 Receptor Antagonistsbeta-ArrestinsClathrinDynaminsGTP-Binding ProteinsLipidsNeurokinin-1 Receptor AntagonistsReceptors, Neurokinin-1Substance P

Identifiers

PMID28566424
PMCPMC6034632
OpenAlexW2620612676

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.